EyePoint Pharmaceuticals Inc

-0.07 (-0.63%)
Earnings Announcements

EyePoint Pharmaceuticals Reports Q2 Loss Per Share Of $0.52

Published: 08/03/2022 11:31 GMT
EyePoint Pharmaceuticals Inc (EYPT) - Eyepoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments.
Q2 Loss per Share $0.52.
Q2 Revenue $11.6 Million.
Cash and Investments at June 30, 2022 Totaled $171.2 Million Compared to $190.8 Million at March 31, 2022.
Cash Runway Into Second Half of 2024.
Revenue is expected to be $10.93 Million
Adjusted EPS is expected to be -$0.68

Next Quarter Revenue Guidance is expected to be $10.27 Million
Next Quarter EPS Guidance is expected to be -$0.72

More details on our Analysts Page.